Clearside Biomedical — Corporate Update (July 2024)
43 slides from Clearside Biomedical's corporate update, Jul 24, 2024
Slide 1: Suprachoroidal Space Drug Delivery
Suprachoroidal Space Drug Delivery July 24, 2024 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Agenda
Agenda 01 02 03 04 05 Versatility of Suprachoroidal Delivery George Lasezkay, PharmD, JD, Clearside President & CEO Real World Use of Suprachoroidal Delivery Glenn Yiu, MD, PhD, Professor of Ophthalmology, University of California, Davis Pipeline Opportunities Victor Chong, MD, MBA, Clearside Chief
Slide 4: Versatility of Suprachoroidal Delivery
GEORGE LASEZKAY, PharmD, JD Clearside President & Chief Executive Officer Versatility of Suprachoroidal Delivery 4
Slide 5: Delivering on the Potential of the Suprachoroidal Space
Delivering on the Potential of the Suprachoroidal Space Proven Leader in Suprachoroidal Delivery with Thousands of Injections Performed Validated Technology with Approved Product, Multiple Collaborations, and Comprehensive IP Portfolio Differentiated Clinical Program Targeting Multi-Billion Dollar W
Slide 6: Proven Leader in Suprachoroidal Delivery
Proven Leader in Suprachoroidal Delivery Formulation Expertise Proprietary Microinjector with Significant Clinical Experience ISO Certified Commercial Scale Injector Manufacturing Capability Experience in Navigating the Drug/Device Regulatory Pathway 1st FDA Product Approved for SCS Administration P
Slide 7: Diverse Programs Using Clearside's Suprachoroidal Injection Platform
Diverse Programs Using Clearside’s Suprachoroidal Injection Platform 1XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb. 2In China, Arctic Vision is responsible for clinical development of ARCAT
Slide 8: Real World Use of Suprachoroidal Delivery
GLENN C. YIU, MD, PhD Professor of Ophthalmology, University of California, Davis Real World Use of Suprachoroidal Delivery 8
Slide 9: Suprachoroidal Drug Delivery: Accessing the suprachoroidal space
Jung et al., Drug Discovery Today, 2019 Naftali & Moisseiev, Pharmaceutics, 2021 Suprachoroidal Drug Delivery Accessing the suprachoroidal space Microneedle Microcatheter orbitsds.com clearsidebio.com 9
Slide 10: Suprachoroidal Drug Delivery: OCT shows SCS expansion
Suprachoroidal Drug Delivery OCT shows SCS expansion after SC injection in humans Baseline 1 mo 2 mo 3 mo Suprachoroidal Space * * * 10 Lampen et al. OSLI Retina, 2018 Yiu et al., Am J Ophthalmol, 2018
Slide 11: CLS-TA for uveitic macular edema
N = 160 patients with uveitic CME Suprachoroidally injected CLS-TA vs. sham (3:2) at day 0 & week 12 Phase 3 PEACHTREE study Uveitic ME Phase 2 TANZANITE study RVO + CME Phase 1/2 HULK study DME Phase 1/2 OASIS study nAMD Phase 1/2 HULK study DME Phase 2 TANZANITE study RVO + CME Phase 1/2 OASIS stu
Slide 12: IRIS study of real-world durability
Suprachoroidal Drug Delivery IRIS study of real-world durability of suprachoroidally injected triamcinolone acetonide for uveitic ME Dates: Jan 2022 to Jun 2023 Index date: first suprachoroidal triamcinolone acetonide injection Rescue: any injectable, implanted, or topical cortical steroids Follow-u
Slide 13: Study demographics & comorbidities
Suprachoroidal Drug Delivery Study demographics & comorbidities Abbreviations: DR, diabetic retinopathy; DME, diabetic macular edema; ME, macular edema; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion Abbreviations: SD, standard deviation * This was only evaluated in the 78
Slide 14: Time to rescue with injectable / implantable corticosteroid
Suprachoroidal Drug Delivery Time to rescue with injectable / implantable corticosteroid 100% 80% 60% 40% 20% 0% Weeks IRIS data In PEACHTREE 86.5% did not require rescue therapy by week 24 *In PEACHTREE, all subjects had a second injection at week 12 * PEACHTREE trial Kaplan Meier Estimate 87.7% of
Slide 15: Types of injected / implanted rescue therapy
Suprachoroidal Drug Delivery Types of injected / implanted rescue therapy Fluocinolone acetonide intravitreal implant (0.18mg), 0.8% Fluocinolone acetonide intravitreal implant (0.59mg), 0.8% Subtenon triamcinolone acetonide, 9.8% Dexamethasone intravitreal implant, 21.3% 15
Slide 16: Time to rescue with any corticosteroid
Suprachoroidal Drug Delivery Time to rescue with any corticosteroid (including topical) 100% 80% 60% 40% 20% 0% Weeks Kaplan Meier estimate from IRIS data 75.4% of eyes did not require any corticosteroid by week 24 16
Slide 17: Patient considerations for suprachoroidal injections
Suprachoroidal Drug Delivery Patient considerations for suprachoroidal injections High myopia or axial length Known scleral thinning History of glaucoma or hypotony History of ocular surgery (esp. trabeculectomy or glaucoma shunt) Patient Selection Sensation of “pressure wave” Longer duration of pro
Slide 18: Needle lengths & injection locations
Suprachoroidal Drug Delivery Needle lengths & injection locations Two needle lengths: 900 mm & 1,100 mm Preferred locations: Superotemporal or Inferotemporal 18 Image courtesy of Bausch & Lomb
Slide 19: Suprachoroidal injection technique
Suprachoroidal Drug Delivery Suprachoroidal injection technique Hold the microinjector perpendicular to the ocular surface Ensure firm contact with sclera by maintaining a dimple throughout injection Inject slowly over 5 – 10 seconds Perpendicular Dimple Slow 19 Images courtesy of Bausch & Lomb
Slide 20: Gene Therapy Drug Development for Geographic Atrophy
Suprachoroidal Drug Delivery Gene Therapy Drug Development for Geographic Atrophy To date, intravitreal biologics have failed in geographic atrophy (GA) Biofactory gene therapy uses retinal cells to produce biologics Intravitreal delivery: gene therapy mostly transfects transfects inner retina and n
Slide 21: Conclusion: Key Takeaways
Conclusion Key Takeaways SCS Microinjector® enables targeted in-office delivery to the suprachoroidal space Clearside is the leader with FDA-approved product, XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use to treat uveitic macular edema Durability of suprachoroidally
Slide 22: Pipeline Opportunities
VICTOR CHONG, MD, MBA Clearside Chief Medical Officer Pipeline Opportunities 22
Slide 23: Benefits for Patients and Physicians Using SCS Microinjector Delivery
Benefits for Patients and Physicians Using SCS Microinjector® Delivery Enhanced Safety Much lower risk of endophthalmitis as direct contact to immune system vs intravitreal injection Injectate Flows to Back of the Eye Reduced risk of floaters, snow globe effect, or other visual disturbances No Impla
Slide 24: Competitive Advantage in Needle Gage Diameter
Competitive Advantage in Needle Gage Diameter 22G 25G 30G Outer Diameter of the Needle Relative to the Ocular Tissue Inner Diameter of the Needle Drug Product Passage 30G needle results in less damage to the ocular tissue wound size to the ocular tissue is >4x greater with 22G Needle >2x greater wit
Slide 25: CLS-AX: Wet AMD Clinical Development Program
CLS-AX: Wet AMD Clinical Development Program
Slide 26: Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery
Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery Axitinib High potency TKI with pan-VEGF inhibition Proprietary CLS-AX Suspension Formulation Clearside formulation expertise Delivery via SCS Microinjector® Compartmentalization may eliminate treatment related floaters, haze,
Slide 27: Key CLS-AX Program Features
Key CLS-AX Program Features Differentiated Approach to Targeting Wet AMD Utilizes the same SCS Microinjector device as FDA-approved product XIPERE Competitors’ delivery devices differ from their approved products Objective is to maintain efficacy and reduce the number of injections and required visi
Slide 28: ODYSSEY Phase 2b trial design
* Disease Activity Assessments (DAA): Conducted at Week 12 through 32 to determine need for supplemental treatment. # In CLS-AX arm, following 3 loading doses of aflibercept and initial dose of CLS-AX at Baseline, participants will receive CLS-AX at least every 24 weeks unless more frequently requir
Slide 29: ODYSSEY Phase 2b Key Differences
ODYSSEY Phase 2b Key Differences Every patient in the CLS-AX group will be re-dosed at least once Re-dosing with CLS-AX 36 Week Treatment Duration Anticipated primary endpoint duration of Phase 3 wet AMD study based on FDA draft guidance Other longer duration therapies (other TKIs, gene therapy) nee
Slide 30: ODYSSEY Update
ODYSSEY Update All participants in the study have completed 6 months of treatment Participants in the CLS-AX arm have received two doses of CLS-AX per protocol In July 2024 meeting, the ODYSSEY Safety Review Committee (SRC) reviewed masked safety data and recommended that the trial continue as plann
Slide 31: Our Target Success Measures for ODYSSEY
Our Target Success Measures for ODYSSEY No drug related ocular Severe Adverse Events Majority of participants reach Week 24 without re-treatment BCVA changes from baseline similar at all visits in particular at Week 24 and Week 36 CST changes from baseline similar at all visits in particular at Week
Slide 32: Pipeline Expansion Opportunity in Geographic Atrophy
Pipeline Expansion Opportunity in Geographic Atrophy
Slide 33: Pathology of Age-Related Macular Degeneration (AMD)
Pathology of Age-Related Macular Degeneration (AMD) Wong JHC et al., Front Neurosci 16: 1009599
Slide 34: Choroidal Hypoxia Theory and Choriocapillaris are Damaged First
Choroidal Hypoxia Theory and Choriocapillaris are Damaged First Geographic Atrophy is a Choroidal Disease Choriocapillaris endothelial cells damage with ghost vessels before any significant RPE changes Choriocapillaris (CC) vascular density is significantly lower in GA donor No meaningful difference
Slide 35: Small Molecule Can Access the Diseased Area of the RPE and Choroid
Larger molecules cannot get through Bruch’s membrane So, if given intravitreally, it can only treat the RPE side Aging intensifies disease actions and even peptides might not be able to get through Small Molecule Can Access the Diseased Area of the RPE and Choroid Images modified from Hammadi et al
Slide 36: Suprachoroidal Administration Could Be Preferred Delivery Method
Suprachoroidal Administration Could Be Preferred Delivery Method Setting Distribution Deliver large molecules Deliver small molecules Gene therapy Suprachoroidal Office Posterior segment Not used Suspension RPE and Choroid Intravitreal Office Widespread in eye Standard Implant Mostly ganglion cells
Slide 37: Potential Target Product Profile Aligns with SCS Suspension or Gene Therapy
Potential Target Product Profile (TPP) Aligns with SCS Suspension or SCS Gene Therapy Potential Advantages of Suprachoroidal Delivery in Geographic Atrophy Less invasive, in-office procedure Systemic therapy may be effective, but potential infection risks in this elderly population Local ocular ther
Slide 38: Traditional Target Pathways for Geographic Atrophy
Traditional Target Pathways for Geographic Atrophy Holz FG et al. Ophthalmology 2014, 1079-91 Choroidal perfusion Complement Genetic risk HTRA1 Mast cell microglia, macrophage Neuro protection Lipids oxidation Lipo fuscin
Slide 39: Large Practice View of Suprachoroidal Delivery
DAVID M. BROWN, MD Director of Research, Retina Consultants Houston Large Practice View of Suprachoroidal Delivery 39
Slide 40: IVT vs SCS Procedure Time Comparison in Optimized High-Volume Practice
Suprachoroidal (SCS) Timeline Intravitreal (IVT) Timeline Patient Travel: 45min round trip Exam: 15min Imaging: 15min Set-Up Anesthesia Sterile Prep (2min) Post Injection (0.5min) Injection as Percentage of Total Time: 0.57%* 5min 5min Injection (0.5 min) Injection (1.0 min) 30 sec increase in docto
Slide 41: Learning from Phase 3 Designs of Aflibercept 8mg and Faricimab
Understanding wet AMD patients have variable dosing frequency requirements Aflibercept 8mg and Faricimab extension criteria are not typically used in clinical practice However, physicians are using them as a replacement of other anti-VEGF in Treat and Extend Ideal Phase 3 design for longer duration
Slide 42: Discussion with Dr. Brown
Discussion with Dr. Brown 42
Slide 43: TM
Nasdaq: CLSD TM